A NOVEL RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN AND SAXAGLIPTIN IN BULK AND PHARMACEUTICAL DOSAGE FORM

被引:10
作者
Aswini, R. [1 ]
Eswarudu, M. Mukkanti [1 ]
Babu, P. Srinivasa [1 ]
机构
[1] Vignan Pharm Coll, Dept Pharmaceut Anal & Qual Assurance, Guntur 522213, Andhra Pradesh, India
关键词
Dapagliflozin; Saxagliptin; RP-HPLC; Validation;
D O I
10.13040/IJPSR.0975-8232.9(12).5161-67
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present work, a rapid, specific, accurate and precise Reversed phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous determination of Dapagliflozin and Saxagliptin in bulk and pharmaceutical dosage form. Successful chromatographic separation of Dapagliflozin and Saxagliptin was carried out with Inertsil-ODS, C-18 column (250 x 4.6 mm; 5 mu m) with mobile phase consisted of a mixture of Methanol and Potassium dihyrogen phosphate buffer in the ratio of 45:55 v/v delivered at a flow rate of 1.0 ml/min. The eluents are monitored by PDA detector and peaks values were measured at 210 nm. The retention times for Dapagliflozin and Saxagliptin were 4.707 min and 6.684 min respectively. The present analytical method was validated according to ICH guidelines (ICH, Q2 R1). The linearity study of Dapagliflozin and Saxagliptin was found in the concentration range of 20-70 mu g/ml and 20-70 mu g/ml respectively and coefficient of variance was 0.999 for both drugs. % recovery was found to be 100.37% and 100.16% for Dapagliflozin and Saxagliptin respectively. LOD was 0.109 mu g/ml and 0.58 mu g/ml and LOQ was 0.332 mu g/ml and 1.77 mu g/ml for Dapagliflozin and Saxagliptin respectively. It inferred that the developed method was successfully applied for the simultaneous estimation of Dapagliflozin and Saxagliptin in bulk and its commercial pharmaceutical dosage forms and could be used for the routine analysis of the studied drugs in quality control laboratories.
引用
收藏
页码:5161 / 5167
页数:7
相关论文
共 39 条
[1]  
Abdalla SA, 2014, INDOAMERICAN J PHARM, P3550
[2]   Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes [J].
Anderson, Rose ;
Hayes, Jennifer ;
Stephens, Jeffrey W. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (04) :467-473
[3]  
[Anonymous], 2005, GUIDELINE ICH HARMON, V1, P05
[4]   Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma [J].
Aubry, Anne-Francoise ;
Gu, Huidong ;
Magnier, Reynald ;
Morgan, Ling ;
Xu, Xiaohui ;
Tirmenstein, Mark ;
Wang, Bonnie ;
Deng, Yuzhong ;
Cai, Jinnan ;
Couerbe, Philippe ;
Arnold, Mark .
BIOANALYSIS, 2010, 2 (12) :2001-2009
[5]   Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].
Augeri, DJ ;
Robl, JA ;
Betebenner, DA ;
Magnin, DR ;
Khanna, A ;
Robertson, JG ;
Wang, AY ;
Simpkins, LM ;
Taunk, P ;
Huang, Q ;
Han, SP ;
Abboa-Offei, B ;
Cap, M ;
Xin, L ;
Tao, L ;
Tozzo, E ;
Welzel, GE ;
Egan, DM ;
Marcinkeviciene, J ;
Chang, SY ;
Biller, SA ;
Kirby, MS ;
Parker, RA ;
Hamann, LG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037
[6]  
Caglar S, 2014, J ANAL BIOANAL TECH, V12, P1
[7]   In Vitro Dissolution Profile of Dapagliflozin: Development, Method Validation, and Analysis of Commercial Tablets [J].
Cavalheiro de Meira, Rafaela Zielinski ;
Maciel, Aline Biggi ;
Murakami, Fabio Seigi ;
de Oliveira, Paulo Renato ;
Bernardi, Larissa Sakis .
INTERNATIONAL JOURNAL OF ANALYTICAL CHEMISTRY, 2017, 2017
[8]  
Chhabda P, 2014, INT J RES DEV PHARM, V3, P993
[9]  
Chitra KP., 2015, J CHEM PHARM RES, V7, P45
[10]  
Cumar RP, 2012, RASAYAN J CHEM, V5, P137